CytomX Therapeutics CTMX Cx801Ifnalpha2B — Total External Costs

Similar metrics at other companies

ARVNOther programs — Program-specific external expense

$2.6M+52.9%

IDYAIDE397 — External Clinical Development Expenses

$3.52M-6.0%

IDYAIDE849 — External Clinical Development Expenses

$4.77M+1,026%

ANROALTO-203 — Direct external program expenses:

$6K-99.2%

IDYAIDE892 — External Clinical Development Expenses

$2.18M+153%

IDYAIDE161 — External Clinical Development Expenses

$1.61M-34.4%

Questions, answered.

What is CytomX Therapeutics's cx801ifnalpha2b — total external costs?

CytomX Therapeutics (CTMX) reported cx801ifnalpha2b — total external costs of $344K in Q1 2026.

How has CytomX Therapeutics's cx801ifnalpha2b — total external costs changed year-over-year?

CytomX Therapeutics's cx801ifnalpha2b — total external costs decreased by 29.5% year-over-year, from $488K to $344K.

What is the long-term trend for CytomX Therapeutics's cx801ifnalpha2b — total external costs?

Over 2 years (2023 to 2025), CytomX Therapeutics's cx801ifnalpha2b — total external costs has grown at a -62.6% compound annual growth rate (CAGR), from $11.62M to $1.63M.

What does cx801ifnalpha2b — total external costs mean?

This metric represents the aggregate third-party expenditures directly attributable to the research, development, and clinical advancement of the specific therapeutic candidate. It captures outsourced costs such as contract research organization fees, manufacturing services, and clinical trial site expenses associated with this program. Monitoring these costs provides insight into the capital intensity and development stage progression of the asset within the company's broader oncology pipeline.